Table 4.
Vaccination date-based analysis of patient characteristics and FDG PET/CT findings of study cohort (n = 140)
| Characteristics | Post 1. vaccination (n = 48) | Post 2. vaccination (n = 92) | p valuea |
|---|---|---|---|
| Patient age, years | 64 ± 13 (33–91) | 68 ± 13 (25–94) | 0.024 |
| Sex, male | 35 (73%) | 66 (72%) | 0.883 |
| Vaccine | < 0.001 | ||
| Pfizer-BioNTech | 18 (38%) | 72 (78%) | |
| Moderna | 30 (62%) | 20 (22%) | |
| Injection site | 0.859 | ||
| Right arm | 10 (21%) | 18 (20%) | |
| Left arm | 38 (79%) | 74 (80%) | |
| Day post vaccination, days | 15 ± 9 (0–40) | 18 ± 12 (0–48) | 0.268 |
| Patients with avid lymph nodes | 27 (56%) | 48 (52%) | 0.647 |
| Pfizer-BioNTech | 7 (39%) | 32 (44%) | 0.787 |
| Moderna | 20 (67%) | 16 (80%) | 0.682 |
| SUVmax of avid lymph node | 4.1 ± 1.7 (2.1–8.2) | 5.4 ± 3.5 (2.0–17.3) | 0.393 |
Values are means ± standard deviations (range), or frequencies (percentages)
aWilcoxon test for paired non-parametric data and chi-squared-test for non-paired, non-parametric data